A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols (Sativex®), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis

Background: Spasticity is a disabling complication of multiple sclerosis, affecting many patients with the condition. We report the first Phase 3 placebo‐controlled study of an oral antispasticity agent to use an enriched study design. Methods: A 19‐week follow‐up, multicentre, double‐blind, rando...

Full description

Saved in:

Bibliographic Details
Published in:	European journal of neurology Vol. 18; no. 9; pp. 1122 - 1131
Main Authors:	Novotna, A., Mares, J., Ratcliffe, S., Novakova, I., Vachova, M., Zapletalova, O., Gasperini, C., Pozzilli, C., Cefaro, L., Comi, G., Rossi, P., Ambler, Z., Stelmasiak, Z., Erdmann, A., Montalban, X., Klimek, A., Davies, P.
Format:	Journal Article
Language:	English
Published:	Oxford, UK Blackwell Publishing Ltd 01.09.2011 John Wiley & Sons, Inc
Subjects:	Adult Aged Cannabidiol cannabinoids Clinical trials delta-9-tetrahydrocannabinol Double-Blind Method Dronabinol Drug Combinations endocannabinoid system Female Humans Male Middle Aged Multiple sclerosis Multiple Sclerosis - complications Multiple Sclerosis - drug therapy Muscle Spasticity - drug therapy Muscle Spasticity - etiology nabiximols Plant Extracts - therapeutic use Sativex Sleep spasticity
ISSN:	1351-5101, 1468-1331, 1468-1331
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!